← Back to Search

ERAS Anesthesia Techniques for Knee Surgery Recovery (EKAT-TeleTPS Trial)

N/A
Recruiting
Led By David Kim, MD
Research Sponsored by Hospital for Special Surgery, New York
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-operative day 1-2 (24-48 hours post spinal induction)

Summary

This trial compares two different ways of numbing the area around the knee during surgery.

Who is the study for?
This trial is for English-speaking adults aged 18-65 with osteoarthritis, scheduled for knee replacement surgery using regional anesthesia. They must live within an hour of the hospital, be able to follow the study protocol, have a smartphone, and have home caregivers if needed. Excluded are those with diabetes, chronic pain or high pain catastrophizing scores, severe knee deformities, no home caregivers for catheter care, ASA status III/IV patients, those unable to manage a catheter at home or going to rehab facilities post-surgery.
What is being tested?
The trial compares two anesthesia techniques in knee replacements: one uses a single-shot nerve block plus local injections (PAI & IPACK), while the other adds a continuous nerve block through a catheter (ACC). The goal is to see which method provides better pain control during recovery.
What are the potential side effects?
Potential side effects may include discomfort at the injection site(s), possible infection risk from the catheter placement for continuous nerve blocks and potential numbness or weakness in the leg temporarily due to nerve blocks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-operative day 1-2 (24-48 hours post spinal induction)
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-operative day 1-2 (24-48 hours post spinal induction) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Opioid consumption during 24-48 hour period
Secondary study objectives
Opioid consumption during post-anesthesia care unit (PACU) stay

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Continuous Adductor Canal Catheter (ACC)Active Control1 Intervention
Patients will receive a combined spinal epidural, PAI, IPACK, and a continuous adductor canal catheter
Group II: Adductor Canal block with sham catheterPlacebo Group1 Intervention
Patients will receive a combined spinal epidural, PAI, IPACK, and an adductor canal block. The patient will also receive a sham catheter.

Find a Location

Who is running the clinical trial?

Hospital for Special Surgery, New YorkLead Sponsor
250 Previous Clinical Trials
61,242 Total Patients Enrolled
David Kim, MDPrincipal InvestigatorHospital for Special Surgery, New York
1 Previous Clinical Trials
112 Total Patients Enrolled

Media Library

Adductor Canal block with sham catheter Clinical Trial Eligibility Overview. Trial Name: NCT03747146 — N/A
Anesthesia Research Study Groups: Continuous Adductor Canal Catheter (ACC), Adductor Canal block with sham catheter
Anesthesia Clinical Trial 2023: Adductor Canal block with sham catheter Highlights & Side Effects. Trial Name: NCT03747146 — N/A
Adductor Canal block with sham catheter 2023 Treatment Timeline for Medical Study. Trial Name: NCT03747146 — N/A
~12 spots leftby Dec 2025